GlassScriptPhysician profile
Norman B Stevens
NPI 1679544001
$5,013.48
in general payments reported to CMS, 2019-2025
37 companies · $673 in 2025
The $673 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $335 · 2021: $731 · 2022: $849 · 2023: $944 · 2024: $810 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,426.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $943.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $628.32 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $404.42 | 2019-2025 | |
| Astellas Pharma US INC | $310.93 | 2019-2021 | |
| Abbvie INC. | $244.08 | 2020-2024 | Vraylar |
| Abbott Laboratories | $242.26 | 2022-2025 | Mitraclip, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $201.29 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $197.19 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $183.24 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $164.15 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.95 | 2020-2023 | Xifaxan, Trulance |
| Bausch Health US, LLC | $122.90 | 2021-2024 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $119.70 | 2019-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.09 | 2019-2025 | Jardiance |
| Edwards Lifesciences Corporation | $108.33 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.